First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey.
BACKGROUND
We aimed to explore the use of platinum plus bevacizumab in a real world NSCLC population.


METHODS
We retrospectively collected data from patients affected by NS-NSCLC treated with platinum plus bevacizumab across Tuscany.


RESULTS
We evaluated 62 (median age: 63.5 [30-77] years) pts. All but one presented with adenocarcinoma and the majority had ECOG PS of 0/1. 17.7% presented with central lesion, 11.3% with brain metastasis, 38.7% with hypertension and 4.8% with mild haemoptysis. We observed a median time to progression (TTP) of 6.5 [2-37] and a median overall survival (OS) of 10.5 [2-39] months. Overall response rate (ORR) was 59.6% with a disease control rate (DCR) of 80.6%. Safety profile was acceptable. We observed five cardiovascular events and two major bleedings with no toxic deaths.


CONCLUSIONS
Safety and efficacy real world data are consistent with those from clinical trials even in a less selected population.
a Medical Oncology , Versilia Hospital and Istituto Toscano Tumori , Lido di Camaiore (LU) , Italy.
Andrea
A
Camerini
b Cardiac and Thoracic Department , Pneumo-Oncology Day Hospital , Pisa , Italy.
Antonio
A
Chella
c SC Medical Oncology , AOU Careggi , Firenze , Italy.
Francesca
F
Mazzoni
a Medical Oncology , Versilia Hospital and Istituto Toscano Tumori , Lido di Camaiore (LU) , Italy.
Cheti
C
Puccetti
a Medical Oncology , Versilia Hospital and Istituto Toscano Tumori , Lido di Camaiore (LU) , Italy.
Sara
S
Donati
c SC Medical Oncology , AOU Careggi , Firenze , Italy.
Alice
A
Lunghi
c SC Medical Oncology , AOU Careggi , Firenze , Italy.
Paolo
P
Petreni
a Medical Oncology , Versilia Hospital and Istituto Toscano Tumori , Lido di Camaiore (LU) , Italy.
Gianna
G
Tartarelli
b Cardiac and Thoracic Department , Pneumo-Oncology Day Hospital , Pisa , Italy.
Massimiliano
M
Serradori
c SC Medical Oncology , AOU Careggi , Firenze , Italy.
Francesco
F
Di Costanzo
a Medical Oncology , Versilia Hospital and Istituto Toscano Tumori , Lido di Camaiore (LU) , Italy.
Domenico
D
Amoroso
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007558:Italy; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D017671:Platinum Compounds / Q000008:administration & dosage; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D017671:Platinum Compounds; D000068258:Bevacizumab
Bevacizumab; Chemotherapy; Non-small-cell lung cancer; Survey